CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....